Journals / Eklem Hastalıkları ve Cerrahisi Dergisi (Eski Adı: Artroplasti Artroskopik Cerrahi Derg.) / 2012 / Cilt: 23 - Sayı: 3

Long-term use of fonduparinux in major orthopedic surgery

Fondaparinuksun majör ortopedik cerrahide uzun süreli kullanımı

Pages
168–172
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further large-scale studies including control groups are required to establish the effects of long-term use of fondaparinux.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate whether the usage of fondaparinux sodium may result in major hemorrhages following major orthopedic surgery.Patients and methods: Forty-three patients (30 females and 13 males; mean age 66 years; range 34 to 94 years) at the age of >18 years who were scheduled for major orthopedic surgery were included.
📊
Key Findings & Data:Prophylaxis was administered with 2.5 mg fondaparinux sodium once daily subcutaneously.
💡
Conclusion & Impact:However, further large-scale studies including control groups are required to establish the effects of long-term use of fondaparinux.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate whether the usage of fondaparinux sodium may result in major hemorrhages following major orthopedic surgery.Patients and methods: Forty-three patients (30 females and 13 males; mean age 66 years; range 34 to 94 years) at the age of >18 years who were scheduled for major orthopedic surgery were included. Total hip arthroplasty, total knee arthroplasty and proximal femur fracture surgeries were defined as the major orthopedic surgeries. Prophylaxis was administered with 2.5 mg fondaparinux sodium once daily subcutaneously. Prophylaxis was initiated at 6-8 hours after the closure of incision. During the prophylaxis period (31±3 days), the patients were monitored for symptomatic deep venous thrombosis. Serum creatinine, platelet and hemoglobin levels were measured at the baseline and in the first week and at one month postoperatively. Wound healing time, healing complications, and major/minor hemorrhages seen during the prophylaxis period were recorded.Results: During the follow-up, none of the patients had symptomatic deep vein thrombosis or symptomatic pulmonary embolism. Two patients (4.6%) had delayed wound healing, while four (9.3%) had minor ecchymosis. No major hemorrhages were observed in any patients.Conclusion: With the long-term use of fondaparinux, we did not observe any major hemorrhagic complications. However, further large-scale studies including control groups are required to establish the effects of long-term use of fondaparinux.

Özet

Amaç: Majör ortopedik cerrahi sonrasında uzun süreli fon-daparinuks sodyum kullanımının majör kanmaya yol açıp açmadığı araştırıldı.Hastalar ve yöntemler: Majör ortopedik ameliyat planlanan 18 yaşından büyük 43 hasta (30 kadın, 13 erkek; ort. yaş 66 yıl: dağılım 34-94 yıl) çalışmaya alındı. Total kalça protezi, total diz protezi ve proksimal femur uç kırığı ameliyatları majör ortopedik ameliyatlar olarak belirlendi. Profilaksi için günde bir kez 2.5 mg fondaparinuks sodyum, subkütan olarak uygulandı. Cerrahi kesi kapatıldıktan 6-8 saat sonra ilk doz profilaksi başlandı. Profilaksi süresince (31±3 gün) hastalarda semptomatik derin ven trombozu takibi yapıldı. Ameliyat öncesi ve ameliyat sonrası birinci haftada ve birinci ayda serum kreatinin, trombosit ve hemoglobin düzeyleri ölçüldü. Yara iyileşme süreleri ve iyileşme komplikasyonları ve profilaksi süresince görülen majör-minör kanamalar kaydedildi.Bulgular: Takipler süresince hiçbir hastada semptomatik derin ven trombozu veya semptomatik pulmoııer emboli saptanmadı. Hastaların ikisinde (%4.6) yara iyileşmesi gecikmesi, dördünde (%9.3) minör ekimoz gelişti. Hiçbir hastada majör kanama görülmedi.Sonuç: Fondaparinuksun uzun süreli kullanımına bağlı olarak majör kanama komplikasyonu gözlenmedi. Ancak fondaparinuks preparatının uzun süreli kullanımda etkilerini ortaya koymak için daha geniş ve kontrol grubu ile yapılan çalışmalara gereksinim vardır.

🔖

Cite This Article

ALTINTAŞ, F., UĞUTMEN, E., ÜNAY, K., ULUÇAY, Ç., GÜVEN, M. (2022). Long-term use of fonduparinux in major orthopedic surgery. Eklem Hastalıkları ve Cerrahisi Dergisi (Eski Adı: Artroplasti Artroskopik Cerrahi Derg.), Cilt: 23 - Sayı: 3, 168–172. https://ajindex.com/articles/498653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Brenkel IJ. DVT prophylaxis in patients undergoing total hip arthroplasty. Curr Orthop 2001;15:356-63
  2. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001;16:293-300
  3. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg [Am) 2000;82:929-38
  4. Ercan Ş. Altıntaş F. Tromboembolizin dekstran 70 ile profilaksisi. Göztepe Tıp Dergisi 1987;2:31-5
  5. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. Fondaparinux. J Am Acad Orthop Surg 2004;12:371-5
  6. Bauer KA, Flawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20:37-52
  7. Turpie AG, Gallus AS, Hoek JA; Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-25
  8. Kurt N, Tolunay M, Asian BY. Total kalça protezi operasyonlarında postoperative venöz yetmezlik derin ven trombozu genel ve epidural anestezinin etkileri. Eklem Hastalik Cerrahisi 2002;13:215-20
  9. White RH. The epidemiology of venous thromboembolism. Circulation 2003,107(23 Suppl l):I4-8
  10. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-64
  11. Hirsh J. Fondaparinux. Hamilton: BC Decker Inc; 2007
  12. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S 13. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004,110(9 Suppl l):I19-26
  13. Turpie AC, Bauer KA, Eriksson BI( Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004;126:501-8
  14. Cruberg L, Beyar R. Optimized combination of antiplatelet treatment and anticoagulation for percutaneous coronary intervention: the final word is not out yet! J Invasive Cardiol 2002;14:251-3
  15. Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary interventi